4-AcO-DET Facts
Psychedelic;
Description
4-AcO-DET (4-acetoxy-N,N-diethyltryptamine) — also known as ethacetin — is a synthetic psychedelic of the tryptamine class. It is a prodrug structural analog of psilocybin, converted by the body into 4-HO-DET, the active compound.[1] That active compound activates serotonin receptors in the brain, producing the visual and introspective shifts characteristic of classical psychedelics.
Subjective effects include brightened colors, geometry, emotional intensification, time alteration, and ego dissolution. The experience is qualitatively similar to psilocybin but shorter — an emotionally vivid, introspective tryptamine state with strong visual and philosophical dimensions.
4-AcO-DET is not habit-forming and produces no physical dependence.[2] The primary danger is psychological — panic and potential triggering of psychotic episodes in predisposed individuals — compounded by combining with serotonin-raising drugs like MAOIs and tramadol, which can cause dangerous overheating.
Dose and durationby route · individual sensitivity varies
Starts in 20 – 60 minLasts 4 – 7 hoursAfter-effects 2 – 4 hours
Body and dependence
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Physical dependence
- None
- Psychological dependence
- Negligible
- Withdrawal
- None recorded
- Compulsive redosing
- Negligible
Tolerance
- Builds
- Rapid
- Fully resets after
- 7 days
- Carries over to
- psilocybin;
psilocin; LSD; DMT; mescaline; 4-AcO-DMT
Effectslikely at a common dose
- Perception
- Music enhancement;
Color enhancement; Visual drifting; Color alteration; Brightness alteration; Geometry; Visual breathing; +28 possible, including Visual haze / noise, Spatial disorientation, Vestibular distortion - Body
- Pupil dilation;
Body high; Body scan awareness; +32 possible, including Insomnia, Nausea, Motor control impairment - Thinking
- Thought connectivity;
Pattern recognition enhancement; Aesthetic enhancement; Introspection enhancement; Openness enhancement; +30 possible, including Cognitive impairment, Memory suppression, Decision impairment - Feeling
- Emotional enhancement;
+8 possible, including Emotional lability, Anxiety, Paranoia - Self
- none likely · 9 possible, including Derealization, Depersonalization
- Time
- Time alteration;
+3 possible, including Temporal disorientation - Transpersonal
- none likely · 1 possible
- Awareness
- none likely · 5 possible
Who shouldn't take it
Combinations61 recorded
Seek help immediately if
Most difficulty is psychological (intense fear, panic, confusion) and passes with calm support — the signs below mean seek emergency help:
- Very high body temperature; hot, dry skin
- Seizures
- Chest pain; fast or irregular heartbeat
- Severe muscle rigidity, tremor, or twitching (possible serotonin syndrome)
- Cold, pale, or blue fingers/toes — severe vasoconstriction (notably NBOMe / DOx)
- Persistent vomiting; unconsciousness; uncontrollable agitation or risk of self-harm
What to do
- Stay calm and reassure — remind them they took a drug and the effect will pass
- Move to a calm, quiet, safe space with low light; reduce noise and sensory input
- Keep them from harm — they may act on fear or confusion; stay with them, don't leave them alone
- Talk them down gently; don't grab or restrain unless they're in danger
- For the medical signs above (overheating, seizure, chest pain, vasoconstriction, unresponsive) call emergency services
- If overheating, cool the body; be ready to give rescue breaths / CPR
The experience is time-limited and usually resolves with calm reassurance in a safe setting — psychological first aid, not medication. Serious physical harm is uncommon for classic psychedelics (LSD, psilocybin) but real for some potent phenethylamines (NBOMe, DOx), where hyperthermia, seizures, and vasoconstriction warrant emergency care.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]^Raithatha SA, Hagel JM, Matinkhoo K, Yu L, Press D, Cook SG, et al. (2024) Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders — Journal of Medicinal Chemistry doi:10.1021/acs.jmedchem.3c01225
- [2]^de la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170